BRPI0518952A2 - mÉtodo para a produÇço de um agente de contraste marcador ou um agente terapÊutico, agentes de contraste marcadores, e, uso dos agentes de contraste marcadores ou dos agentes terapÊuticos de marcaÇço - Google Patents

mÉtodo para a produÇço de um agente de contraste marcador ou um agente terapÊutico, agentes de contraste marcadores, e, uso dos agentes de contraste marcadores ou dos agentes terapÊuticos de marcaÇço

Info

Publication number
BRPI0518952A2
BRPI0518952A2 BRPI0518952-7A BRPI0518952A BRPI0518952A2 BR PI0518952 A2 BRPI0518952 A2 BR PI0518952A2 BR PI0518952 A BRPI0518952 A BR PI0518952A BR PI0518952 A2 BRPI0518952 A2 BR PI0518952A2
Authority
BR
Brazil
Prior art keywords
agents
marker contrast
therapeutic
agent
marker
Prior art date
Application number
BRPI0518952-7A
Other languages
English (en)
Inventor
Helga Hummel
Volker U Weiler
Ralf Hoffmann
Original Assignee
Koninkl Philips Electronics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninkl Philips Electronics Nv filed Critical Koninkl Philips Electronics Nv
Publication of BRPI0518952A2 publication Critical patent/BRPI0518952A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
    • A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mathematical Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODO PARA A PRODUÇçO DE UM AGENTE DE CONTRASTE MARCADOR OU UM AGENTE TERAPÊUTICO, AGENTES DE CONTRASTE MARCADORES, E, USO DOS AGENTES DE CONTRASTE MARCADORES OU DOS AGENTES TERAPÊUTICOS DE MARCAÇçO. Esta invenção diz respeito a um método de sintetizar agentes de contraste para formação de imagem molecular e diagnóstico e terapia de marcação, agentes de contraste marcadores e agentes terapêuticos marcadores, e seu uso.
BRPI0518952-7A 2004-12-17 2005-12-12 mÉtodo para a produÇço de um agente de contraste marcador ou um agente terapÊutico, agentes de contraste marcadores, e, uso dos agentes de contraste marcadores ou dos agentes terapÊuticos de marcaÇço BRPI0518952A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04106694 2004-12-17
PCT/IB2005/054185 WO2006064451A2 (en) 2004-12-17 2005-12-12 Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy

Publications (1)

Publication Number Publication Date
BRPI0518952A2 true BRPI0518952A2 (pt) 2008-12-16

Family

ID=36174791

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518952-7A BRPI0518952A2 (pt) 2004-12-17 2005-12-12 mÉtodo para a produÇço de um agente de contraste marcador ou um agente terapÊutico, agentes de contraste marcadores, e, uso dos agentes de contraste marcadores ou dos agentes terapÊuticos de marcaÇço

Country Status (7)

Country Link
US (1) US20090238767A1 (pt)
EP (1) EP1827506A2 (pt)
JP (1) JP2008524202A (pt)
CN (1) CN101080240A (pt)
BR (1) BRPI0518952A2 (pt)
RU (1) RU2007127314A (pt)
WO (1) WO2006064451A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117883596A (zh) * 2022-10-09 2024-04-16 中国科学院苏州纳米技术与纳米仿生研究所 一种乏氧响应的t1-t2可切换型mri造影剂、其制备方法及应用

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
EP1921081A1 (en) * 2006-11-06 2008-05-14 Koninklijke Philips Electronics N.V. Use of arylboronic acids in protein labelling
AU2008212820B2 (en) 2007-02-09 2014-01-30 Northwestern University Particles for detecting intracellular targets
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
GB0709561D0 (en) * 2007-05-18 2007-06-27 Siemens Medical Solutions Assessment of vascular compartment volume PET modeling
EP2005973A1 (de) 2007-06-22 2008-12-24 nanoPET Pharma GmbH Positronen emittierende anorganische Partikel enthaltende Zusammensetzungen und deren Verwendung in der Medizin, insbesondere für diagnostische Verfahren
KR101031049B1 (ko) 2008-04-17 2011-04-25 한국생명공학연구원 다기능성 퍼플루오르카본 나노 에멀젼을 이용한 세포 표지및 영상화
GB0811856D0 (en) 2008-06-27 2008-07-30 Ucl Business Plc Magnetic microbubbles, methods of preparing them and their uses
KR101094207B1 (ko) * 2008-08-21 2011-12-14 연세대학교 산학협력단 Ｔ１―ｔ２ 이중방식 ｍｒｉ 조영제
JP5427329B2 (ja) * 2008-08-30 2014-02-26 国立大学法人九州大学 金微粒子とその製造方法
EP2359852A4 (en) 2008-11-17 2015-05-20 Nat Cancer Ct NEW CANCERED THERAPY WITH A SUBSTANCE COMPLEX SPECIFICALLY BINDING TO A TUMOR STREAM FACTOR AND ANTITUMIR COMPOUND
AU2009316286B2 (en) 2008-11-24 2016-05-26 Northwestern University Polyvalent RNA-nanoparticle compositions
US9399075B2 (en) 2008-12-29 2016-07-26 General Electric Company Nanoparticle contrast agents for diagnostic imaging
JP6063627B2 (ja) * 2008-12-29 2017-01-18 ゼネラル・エレクトリック・カンパニイ 診断イメージング用のナノ粒子造影剤
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
EP2398503B1 (en) * 2009-02-13 2018-10-31 University Of Washington Gadolinium expressed lipid nanoparticles for magnetic resonance imaging
ES2627420T3 (es) * 2009-06-12 2017-07-28 Erasmus University Medical Center Rotterdam Nanofotomedicamentos destinados al tratamiento fotodinámico del cáncer
US20120277283A1 (en) * 2009-08-04 2012-11-01 Mirkin Chad A Localized Delivery of Gold Nanoparticles for Therapeutic and Diagnostic Applications
WO2011017690A2 (en) * 2009-08-07 2011-02-10 Northwestern University Intracellular delivery of contrast agents with functionalized nanoparticles
CN102666879B (zh) 2009-10-30 2016-02-24 西北大学 模板化的纳米缀合物
EP2493458A2 (en) * 2009-10-30 2012-09-05 The Ohio State University Multi-functional biodegradable particles for selectable targeting, imaging, and therapeutic delivery and use thereof for treating ocular disorders
US9034204B2 (en) * 2009-12-16 2015-05-19 The Regents Of The University Of California Gold coating of rare earth nano-phosphors and uses thereof
EP2416345A1 (en) 2010-08-06 2012-02-08 Philips Intellectual Property & Standards GmbH Particle-based matrix carriers for mass spectrometry
CN102397564B (zh) * 2010-09-19 2013-05-29 复旦大学 一种肿瘤靶向诊断核磁共振造影剂及其制备方法
US10175170B2 (en) 2010-12-16 2019-01-08 The Regents Of The University Of California Metal coating of rare earth nano-phosphors and uses thereof
CN102167813B (zh) * 2011-01-19 2012-08-08 兰州大学 一种荧光示踪纳米磁共振成像造影剂
FI124029B (fi) * 2011-03-24 2014-02-14 Upm Kymmene Corp Menetelmä mikrokapseleiden valmistamiseksi hemiselluloosasta
WO2012138694A2 (en) * 2011-04-07 2012-10-11 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
RU2465010C1 (ru) * 2011-06-08 2012-10-27 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Контрастное средство для магнитно-резонансной томографии
CN102861346A (zh) * 2011-07-08 2013-01-09 复旦大学附属肿瘤医院 细胞凋亡PET/CT活体分子影像探针18F-Annexin B1及其制备方法和用途
CN102881392A (zh) * 2011-07-15 2013-01-16 北京格加纳米技术有限公司 一种功能化磁性颗粒及其合成方法
CN104023749B (zh) 2011-09-14 2019-12-17 西北大学 能穿过血脑屏障的纳米缀合物
CN102430130B (zh) * 2011-11-24 2012-12-12 北京化工大学 一种医药用改性葡聚糖包覆磁性纳米颗粒复合材料及其制备方法
CN102664084B (zh) * 2012-05-22 2014-11-26 中北大学 一种花状Fe2O3/Cu电磁功能复合粒子及其制备方法
CN102688508B (zh) * 2012-05-23 2015-04-15 清华大学 一种靶向放射性微纳米流体制剂
CN102727892A (zh) * 2012-07-06 2012-10-17 陈智毅 一种靶向顺磁性稀土离子光敏探针及其制备方法
KR101599589B1 (ko) * 2012-10-31 2016-03-04 고려대학교 산학협력단 인 비보 이미징을 위한 재조합 형광 단백질 나노입자
KR101473078B1 (ko) 2013-01-02 2014-12-17 연세대학교 산학협력단 암 진단 및 치료용 유-무기 나노복합체
CN103159842B (zh) * 2013-03-18 2015-07-01 江苏省原子医学研究所 一种用于99mTc标记的Cys-Annexin V药盒及其配制方法与应用
CN103159841B (zh) * 2013-03-18 2014-07-02 江苏省原子医学研究所 一种99mTc标记Cys-Annexin V的方法及其应用
CN103240120B (zh) * 2013-05-22 2015-05-13 天津工业大学 一种基于磁性人工细胞的温度开关型催化剂
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
CN104491881A (zh) * 2014-12-05 2015-04-08 北京肿瘤医院 一种荧光偶联的特异性前哨淋巴结显像剂及其制备方法
CN104758954B (zh) * 2015-03-16 2017-08-25 北京化工大学 一种基于金属离子诱导多肽自组装的双功能纳米复合球及其制备方法
GB2541003A (en) * 2015-08-05 2017-02-08 Kran Life Sciences Llp Neurodegenerative disorders
CN105097174B (zh) * 2015-08-12 2018-06-22 华南理工大学 一种木聚糖季铵盐纳米磁性颗粒及其制备方法
KR101852066B1 (ko) * 2016-09-09 2018-04-27 한국과학기술연구원 불소계 용매에 대한 분산성이 향상된 자성 나노입자 및 이의 제조방법
CN107224588B (zh) * 2016-11-08 2020-03-17 暨南大学 一种具有磁-pH值双响应的药物载体的制备方法
CN108245689A (zh) * 2016-12-29 2018-07-06 国家纳米科学中心 用于提高核磁共振检测精确度的造影剂、制备方法及应用
CN107324399B (zh) * 2017-07-12 2019-04-23 海门市彼维知识产权服务有限公司 一种氧化铁纳米材料和用作肿瘤药物靶向载体的用途
CN107469092A (zh) * 2017-08-07 2017-12-15 上海纳米技术及应用国家工程研究中心有限公司 靶向性纳米材料制备方法及其产品和应用
CN108570081B (zh) * 2018-05-25 2020-06-30 西南医科大学附属医院 一种葡萄糖类影像诊断及治疗的配体化合物及制备和应用
CN111024683B (zh) * 2019-12-26 2021-05-07 湖南大学 一种化学发光体系及其制备方法和应用
CN111326302B (zh) * 2020-03-23 2021-10-29 南通三优佳磁业有限公司 一种用于工业清洁空气的核壳结构磁性材料及制备方法
CN111729093B (zh) * 2020-06-29 2022-05-24 南京超维景生物科技有限公司 一种造影剂成膜剂组合物、造影剂成膜脂液、造影剂及其制备方法
CA3190518A1 (en) * 2020-08-06 2022-02-10 Adiposs SA Pet-ct imaging methods, contrast agents and pharmaceutical compositions for use in said imaging methods
CN112940157B (zh) * 2021-03-22 2023-01-10 南方医科大学 一种钆螯合物及其制备方法和应用
TWI886408B (zh) * 2021-09-09 2025-06-11 原創生醫股份有限公司 用於超音波造影之金屬複合物及其用途
CN115825442B (zh) * 2021-11-23 2024-12-24 中国人民解放军总医院第一医学中心 钙钛矿纳米晶在制备用于肿瘤诊断或治疗的探针中的应用
CN116077685B (zh) * 2023-02-17 2024-11-26 成都纽瑞特医疗科技股份有限公司 放射性核素标记的含硼药物及其制备和应用
CN120037403B (zh) * 2025-02-11 2026-03-17 浙江大学医学院附属邵逸夫医院 一种ros响应载药双靶向治疗糖尿病肾病纳米递送系统的制备方法
CN121818971B (zh) * 2026-03-12 2026-06-26 中山大学 一种放射性标记磁性t1-t2协同mri-pet双模态影像探针的构建方法及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017215A1 (en) * 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Contrast media
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
DE69431049T2 (de) * 1993-03-12 2003-03-13 Mallinckrodt, Inc. Stickstoff-schwefel-liganden auf imidazolbasis verwendbar in radiographischen abbildungsmitteln
US6333110B1 (en) * 1998-11-10 2001-12-25 Bio-Pixels Ltd. Functionalized nanocrystals as visual tissue-specific imaging agents, and methods for fluorescence imaging
US7438893B2 (en) * 2003-10-02 2008-10-21 Massachusetts General Hospital Polybiotin compounds for magnetic resonance imaging and drug delivery

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117883596A (zh) * 2022-10-09 2024-04-16 中国科学院苏州纳米技术与纳米仿生研究所 一种乏氧响应的t1-t2可切换型mri造影剂、其制备方法及应用

Also Published As

Publication number Publication date
JP2008524202A (ja) 2008-07-10
US20090238767A1 (en) 2009-09-24
CN101080240A (zh) 2007-11-28
WO2006064451A2 (en) 2006-06-22
RU2007127314A (ru) 2009-01-27
WO2006064451A3 (en) 2007-03-01
EP1827506A2 (en) 2007-09-05

Similar Documents

Publication Publication Date Title
BRPI0519047A2 (pt) mÉtodo para a produÇço de um agente de contraste marcador ou agente terapÊutico marcador, agentes de contraste marcadores e uso de agentes de contraste marcadores ou de agentes terapÊuticos marcadores
BRPI0410503B8 (pt) composição tópica e uso da composição
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
SV2003001107A (es) Imidazotriazinas ref.lea 35368
WO2006064451A3 (en) Targeting contrast agents or targeting therapeutic agents for molecular imaging and therapy
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
BRPI0816597A2 (pt) "composto, composição farmacêutica, combinação, uso de um composto, método para tratar um indivíduo aflifido com uma consição patológica ou doença e método de modulação de uma atividade um receptor b2 adrenérgico"
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
UY28314A1 (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
GT200500359A (es) Compuestos organicos
PT1397145E (pt) Utilizacao de inibidores da cox-2 para o tratamento de esquizofrenia ou de disturbios de tiques
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
BRPI0718469A2 (pt) Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto.
BRPI0716250A2 (pt) Composto ou sal ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças, e, uso de um composto
WO2004025303A3 (en) Isoprostanes as markers of psychological stress in humans
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
PT1255538E (pt) Utilizacao do acido 2-metil-tiazolidin-2,4-dicarboxilico e/ou sais compativeis fisiologicamente para tratamento e/ou prevencao de cancros
BRPI0408238A (pt) anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer
BRPI0507157A (pt) uso de fator viia ou de um equivalente de fator viia, kit de partes para tratamento de trauma, e, métodos para tratar trauma e para prevenir, tratar trauma

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]